INS and metabolic dysfunction-associated steatohepatitis: Defective glucose metabolism and IR are key features of NASH pathophysiology.[74] INS-R activity was increased in the volixibat groups and, at the highest dose, plasma insulin levels were significantly lower than those in the HFD control group, implying an overall improvement in insulin sensitivity with volixibat treatment.